Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TJC0434
- Development stage
- Preclinical
- Lead developer
- TaiwanJ Pharmaceuticals
- Modality
- Small Molecules
01
Overview
TJC0434 is a preclinical-stage small molecule inhibitor developed by TaiwanJ Pharmaceuticals that targets NADPH oxidase (NOX) enzymes. The mechanism of action focuses on reducing the production of reactive oxygen species (ROS), which are known to drive tumorigenic processes and inflammatory signaling. By inhibiting NOX, TJC0434 aims to interfere with ROS-mediated pathways that contribute to cancer progression. While its primary oncology focus is currently in animal studies, the compound has also been explored for its potential in treating other conditions associated with oxidative stress and inflammation, such as gout. TaiwanJ Pharmaceuticals has secured patents for the compound in several regions, including Taiwan, China, and Japan.
Beyond the preview
Go deeper on TJC0434.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TJC0434.